BioPharmaBrief

The discoveries, the decisions, and the capital moving biotech and pharma forward

2 posts

Jon Nugent

Inside Gibson Oncology: From a Compound Library to a Phase II Brain Cancer Trial

Inside Gibson Oncology: From a Compound Library to a Phase II Brain Cancer Trial

Jon Nugent ―

A conversation with Gibson Oncology President and CEO Randall B. Riggs Glioblastoma is the most common and most aggressive primary brain tumor in adults. Roughly 13,000 Americans are diagnosed each year, median survival runs 15 to 18 months, and fewer than one in ten patients are alive at five years. For those whose disease returns, there is no established standard of care. Part of the reason is access. The

Two Pills Take on Markets Built by Injections

Two Pills Take on Markets Built by Injections

Jon Nugent, Logan Mavar ―

Two pills use different molecular strategies to compete in markets established by injected therapies. In less than four months, the FDA approved two pills built around different approaches to oral drug design. Eli Lilly’s Foundayo⁠ activates the GLP-1 receptor with a nonpeptide small molecule. Merck’s Lipfendra⁠ delivers a macrocyclic peptide orally to block PCSK9. Both drugs enter classes whose clinical value was established largely by injected therapies.